Support groundbreaking research
You can help groundbreaking research where the results won’t just be seen in the lab. They’ll be seen in life-changing breakthroughs for thousands of people with Parkinson’s.
Do 2 existing drugs hold the key to slowing or stopping Parkinson’s?
Dr Susan Duty’s investigating the impact 2 already existing drugs have on increasing a protein known for its protective effects on dopamine-producing brain cells.
We already know the loss of dopamine-producing cells cause symptoms of Parkinson's. Boosting the brain’s supply of a protein (called FGF20) could protect dopamine production. This could provide the potential to slow, stop or reverse Parkinson’s
What’s the connection between FGF20 and Parkinson’s?
FGF20 is a protein which occurs naturally in the brain. It’s particularly important in Parkinson’s as it protects dopamine-producing brain cells from degeneration. But there’s not enough FGF20 naturally in the brain to do this. So how do we boost these levels?
Since her grandmother’s Parkinson’s diagnosis, Dr Duty has been determined to tackle Parkinson’s and find a cure. In her first project, she narrowed the search down to 2 drugs which showed potential to boost the brain’s natural production of FGF20, Triflusal and Salbutamol.
Now Dr Duty wants to find out if these 2 drugs will slow down or stop the progression of Parkinson’s in rodent models.
Triflusal and Salbultamol are already used to treat other conditions so if they do boost the levels of FGF20 and slow down or stop the progression of Parkinson’s in rodent models, the clinical trial process can be fast forwarded. This is really exciting, and means we can move to a new treatment much quicker.
This groundbreaking research could be life-changing for people with Parkinson’s. Donate now and be part of the science accelerating these research breakthroughs.